雅各臣科研製藥(02633.HK)中期溢利增長30.5%至1.27億港元 每股派息2港仙
格隆匯11月26日丨雅各臣科研製藥(02633.HK)發佈公告，截至2019年9月30日止6個月，公司收益8.72億港元，同比增長6.8%；經營溢利約為1.88億港元，同比增長18.3%；公司股東應占溢利1.27億港元，同比增長30.5%；每股盈利6.32港仙，中期股息每股普通股2.0港仙。
於報告期，該集團的非專利藥業務錄得5.3%的正數增長，銷售收益達626.9百萬港元。非專利藥分部的整體收益增長令人鼓舞，增幅主要源於其擴展廣泛且具針對性產品組合的擴展，以及人口老齡化及慢性病流行加大了人們對醫療保健的需求所致，儘管私營界別的收益增長一定程度受阻於過去幾個月市內多個主要零售及旅遊區所發生的廣泛持續示威。
期間心血管及中樞神經系統治療等治療類產品的銷售增長強勁。於報告期，該集團心血管產品系列中的β受體抑制劑及鈣拮抗劑類分別錄得25.0%及21.1%的增長。於該集團中樞神經系統產品系列方面，抗精神病藥類錄得15.1%的增長，並獲取利培酮片(Risperidone Tablets)的新招標，而安眠藥類則錄得9.4%的增長。此外，口服糖尿藥類亦因急劇增加的市場需求而達到32.2%的強勢增長。
報告期內，公司的產品研發項目繼續取得良好進展。包括三種不同劑量的託莫西汀膠囊(Atomoxetine Capsules)與甲硝唑凝膠(Metronidazole Gel)等合共4款產品已於報告期內成功註冊，並準備於香港推出供應。八項主要為中樞神經系統類別的其他新產品已完成開發過程，並已向衞生署提交申請以供批核。
截至2019年9月30日，公司正在研發的產品有103項，其中48項已獲准註冊，8項已提交註冊，27項已完成開發階段並正進行穩定性測試程序，另有20項目前正在開發中。於報告期內，公司有7個新增研發項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
